Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active folate supplementation for hyperhomocysteinemia in metabolic syndrome
IRCT20240722062513N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of folate in cardiometabolic risk (CMR) and hyperhomocysteinemia, sponsored by Tehran University of Medical Sciences. Primary endpoint: Change in homocysteine level. Started Aug 2024; status: completed.
02
Drugs
folate
03
Conditions
cardiometabolic risk (CMR)hyperhomocysteinemia
Beyond the preview
Go deeper on IRCT20240722062513N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240722062513N1.